RecruitingNot ApplicableNCT06676085

A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation

A Novel Strategy Combined Regional Anticoagulation in Membrane Oxygenator and Low-intensity of Systemic Anticoagulation Applied in Management of Extracorporeal Membrane Oxygenation


Sponsor

Beijing Chao Yang Hospital

Enrollment

60 participants

Start Date

Nov 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • age older than 18 years old
  • received ECMO because of severe respiratory failure

Exclusion Criteria7

  • anticoagulant contraindications
  • cerebral infarction or suspected patients
  • severe hypertension
  • women in gestational and lactational period
  • hemophilia
  • allergic to heparin or Nafamostat
  • unwilling or unable to complete the study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNafamostat

Nafamostat combined with unfractionated heparin for anticoagulation

DRUGHeparin

unfractionated heparin for anticoagulation


Locations(1)

Bing Sun

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06676085


Related Trials